View in EDS

TP53 co-mutations as an independent prognostic factor in 2nd and further line therapy-EGFR mutated non-small cell lung cancer IV patients treated with osimertinib.

Saved in:
Bibliographic Details
Title: TP53 co-mutations as an independent prognostic factor in 2nd and further line therapy-EGFR mutated non-small cell lung cancer IV patients treated with osimertinib.
Authors: Roeper J; Department of Internal Medicine-Oncology, Carl v. Ossietzky University of Oldenburg, Pius-Hospital, Oldenburg, Germany.; Department of Hematology and Oncology, Pius-Hospital, Oldenburg, Germany.; Lung Cancer Network NOWEL Organisation, Pius-Hospital, Oldenburg, Germany., Christopoulos P; Thoraxklinik and National Center for Tumor Diseases at Heidelberg University Hospital, Heidelberg, Germany.; Translational Lung Research Center Heidelberg (TLRC-H), member of the German Center for Lung Research (DZL), University Hospital, Heidelberg, Germany., Falk M; Lung Cancer Network NOWEL Organisation, Pius-Hospital, Oldenburg, Germany.; Hematopathology Hamburg, Hamburg, Germany., Heukamp LC; Lung Cancer Network NOWEL Organisation, Pius-Hospital, Oldenburg, Germany.; Hematopathology Hamburg, Hamburg, Germany., Tiemann M; Lung Cancer Network NOWEL Organisation, Pius-Hospital, Oldenburg, Germany.; Hematopathology Hamburg, Hamburg, Germany., Stenzinger A; Department of General Pathology and Pathological Anatomy, University Hospital, Heidelberg, Germany., Thomas M; Thoraxklinik and National Center for Tumor Diseases at Heidelberg University Hospital, Heidelberg, Germany.; Translational Lung Research Center Heidelberg (TLRC-H), member of the German Center for Lung Research (DZL), University Hospital, Heidelberg, Germany., Griesinger F; Department of Internal Medicine-Oncology, Carl v. Ossietzky University of Oldenburg, Pius-Hospital, Oldenburg, Germany.; Department of Hematology and Oncology, Pius-Hospital, Oldenburg, Germany.; Lung Cancer Network NOWEL Organisation, Pius-Hospital, Oldenburg, Germany.
Source: Translational lung cancer research [Transl Lung Cancer Res] 2022 Jan; Vol. 11 (1), pp. 4-13.
Publication Type: Journal Article
Journal Info: Publisher: Pioneer Bioscience Publishing Company Country of Publication: China NLM ID: 101646875 Publication Model: Print Cited Medium: Print ISSN: 2218-6751 (Print) Linking ISSN: 22186751 NLM ISO Abbreviation: Transl Lung Cancer Res Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 35242623
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: TP53 co-mutations as an independent prognostic factor in 2nd and further line therapy-EGFR mutated non-small cell lung cancer IV patients treated with osimertinib.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Roeper+J%22">Roeper J</searchLink>; Department of Internal Medicine-Oncology, Carl v. Ossietzky University of Oldenburg, Pius-Hospital, Oldenburg, Germany.; Department of Hematology and Oncology, Pius-Hospital, Oldenburg, Germany.; Lung Cancer Network NOWEL Organisation, Pius-Hospital, Oldenburg, Germany.<br /><searchLink fieldCode="AU" term="%22Christopoulos+P%22">Christopoulos P</searchLink>; Thoraxklinik and National Center for Tumor Diseases at Heidelberg University Hospital, Heidelberg, Germany.; Translational Lung Research Center Heidelberg (TLRC-H), member of the German Center for Lung Research (DZL), University Hospital, Heidelberg, Germany.<br /><searchLink fieldCode="AU" term="%22Falk+M%22">Falk M</searchLink>; Lung Cancer Network NOWEL Organisation, Pius-Hospital, Oldenburg, Germany.; Hematopathology Hamburg, Hamburg, Germany.<br /><searchLink fieldCode="AU" term="%22Heukamp+LC%22">Heukamp LC</searchLink>; Lung Cancer Network NOWEL Organisation, Pius-Hospital, Oldenburg, Germany.; Hematopathology Hamburg, Hamburg, Germany.<br /><searchLink fieldCode="AU" term="%22Tiemann+M%22">Tiemann M</searchLink>; Lung Cancer Network NOWEL Organisation, Pius-Hospital, Oldenburg, Germany.; Hematopathology Hamburg, Hamburg, Germany.<br /><searchLink fieldCode="AU" term="%22Stenzinger+A%22">Stenzinger A</searchLink>; Department of General Pathology and Pathological Anatomy, University Hospital, Heidelberg, Germany.<br /><searchLink fieldCode="AU" term="%22Thomas+M%22">Thomas M</searchLink>; Thoraxklinik and National Center for Tumor Diseases at Heidelberg University Hospital, Heidelberg, Germany.; Translational Lung Research Center Heidelberg (TLRC-H), member of the German Center for Lung Research (DZL), University Hospital, Heidelberg, Germany.<br /><searchLink fieldCode="AU" term="%22Griesinger+F%22">Griesinger F</searchLink>; Department of Internal Medicine-Oncology, Carl v. Ossietzky University of Oldenburg, Pius-Hospital, Oldenburg, Germany.; Department of Hematology and Oncology, Pius-Hospital, Oldenburg, Germany.; Lung Cancer Network NOWEL Organisation, Pius-Hospital, Oldenburg, Germany.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101646875%22">Translational lung cancer research</searchLink> [Transl Lung Cancer Res] 2022 Jan; Vol. 11 (1), pp. 4-13.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Pioneer+Bioscience+Publishing+Company%22">Pioneer Bioscience Publishing Company </searchLink><i>Country of Publication: </i>China <i>NLM ID: </i>101646875 <i>Publication Model: </i>Print <i>Cited Medium: </i>Print <i>ISSN: </i>2218-6751 (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2222186751%22">22186751 </searchLink><i>NLM ISO Abbreviation: </i>Transl Lung Cancer Res <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=35242623
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.21037/tlcr-21-754
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 4
    Titles:
      – TitleFull: TP53 co-mutations as an independent prognostic factor in 2nd and further line therapy-EGFR mutated non-small cell lung cancer IV patients treated with osimertinib.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Roeper J
      – PersonEntity:
          Name:
            NameFull: Christopoulos P
      – PersonEntity:
          Name:
            NameFull: Falk M
      – PersonEntity:
          Name:
            NameFull: Heukamp LC
      – PersonEntity:
          Name:
            NameFull: Tiemann M
      – PersonEntity:
          Name:
            NameFull: Stenzinger A
      – PersonEntity:
          Name:
            NameFull: Thomas M
      – PersonEntity:
          Name:
            NameFull: Griesinger F
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 01
              Text: 2022 Jan
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-print
              Value: 2218-6751
          Numbering:
            – Type: volume
              Value: 11
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Translational lung cancer research
              Type: main
ResultId 1